718610-74-3Relevant articles and documents
Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis
Cumming, John G.,Tucker, Howard,Oldfield, John,Fielding, Colin,Highton, Adrian,Faull, Alan,Wild, Martin,Brown, Dearg,Wells, Stuart,Shaw, John
, p. 1655 - 1659 (2012/04/04)
Modifications to a series of potent and selective substituted 1-(3,3-diphenylpropyl)-piperidine phenylacetamide CCR5 antagonists were explored with the aim of reducing affinity at the hERG cardiac ion channel. Replacement of one aromatic ring in the diphe
Chemical Compound
-
Page/Page column 9-10, (2008/12/06)
The present invention relates to 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine (I): or a pharmaceutically acceptable salt thereof, as well as to processes for preparing
CHEMICAL COMPOUNDS
-
Page/Page column 57, (2008/06/13)
Compounds of formula (I): wherein: when X is NR5, Y is absent or is CH2; when X is CH2, Y is absent, CH2, NR6, O, S, S(O) or S(O)2; Z is a 5- or 6-membered heterocyclyl ring; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).